98%
921
2 minutes
20
Accumulating evidences have shown that unfolded protein response (UPR) contributes to the increased survival of tumor cells under endoplasmic reticulum (ER) stress conditions. Malectin is an ER-resident lectin that selectively traps misfolded glycoproteins in ER for degradation, and its expression is upregulated upon ER stress. However, contribution of malectin to malignant behavior of tumor has not been reported. Here, we revealed that malectin expression is aberrantly up-regulated in human hepatocellular carcinoma (HCC) tissues and HCC cell lines compared to their matched normal tissues and cell lines. Knockout of malectin in two HCC cell lines HepG2 and QGY-7703 using CRISPR-Cas9 technology had no obvious effects on cell proliferation, but significantly suppressed cell colony formation, migration and invasion. Consistently, subcutaneously implanted malectin-deficient HCC cells in nude mice also showed an obvious decrease in tumor growth. These results indicate that malectin might play an oncogenic role in HCC tumorigenesis and development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/glycob/cwaf007 | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFBioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Dr. B. R. Ambedkar Centre for Biomedical Research North Campus , University of Delhi, 110007, Delhi, India.
Background: Standard treatment for glioblastoma includes chemotherapy, alkylating agents such as temozolomide (TMZ); however, MGMT resistance leads to recurrence. Demethoxycurcumin (DMC) has been reported to inhibit cancer cell growth, induce apoptosis, and prevent metastasis in different cancer models. We investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.
View Article and Find Full Text PDFCell Mol Life Sci
September 2025
Department of Gastroenterology, The Second Hospital of Shandong University, Jinan, China.
Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway.
View Article and Find Full Text PDFJ Child Neurol
September 2025
Department of Neurology, Nationwide Children's Hospital, Columbus, OH, USA.
This case report describes the use of doxazosin (Cardura) as a treatment for a patient with an autosomal dominant , single-nucleotide R398Q pathogenic variant, which has not previously been described in the literature. The patient has gain-of-function pathogenic genetic variant. Because of the patient's continued seizure burden with the use of traditional antiseizure medications and failed invasive antiseizure interventions, an oocyte cell line with the specific genetic variant was created to test efficacy of various medications.
View Article and Find Full Text PDF